Regeneron Pharmaceuticals REGN Treasury Stock
Treasury Stock at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's treasury stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's treasury stock?
- Regeneron Pharmaceuticals (REGN) reported treasury stock of $19.41B in Q1 2026.
- How has Regeneron Pharmaceuticals's treasury stock changed year-over-year?
- Regeneron Pharmaceuticals's treasury stock increased by 19.7% year-over-year, from $16.22B to $19.41B.
- What is the long-term trend for Regeneron Pharmaceuticals's treasury stock?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's treasury stock has grown at a 22.5% compound annual growth rate (CAGR), from $8.26B to $18.61B.
- What does treasury stock mean?
- Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.